Myelodysplastic Syndrome Clinical Trials This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

CD34 Selection Using the Automated CliniMACS Prodigy
Conditions: AML; ALL; Lymphoid Malignancies; Myelodysplastic Syndromes; CML; Primary Myelofibrosis Interventions: Drug: Infusion of CD34 selected hematopoietic stem cells Sponsors: University of Alabama at Birmingham Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 21, 2023 Category: Research Source Type: clinical trials

A Study to Assess Luspatercept in Lower-risk Myelodysplastic Syndrome Participants
Conditions: Myelodysplastic Syndromes Interventions: Drug: Luspatercept Sponsors: Bristol-Myers Squibb Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 21, 2023 Category: Research Source Type: clinical trials

Study of SGR-2921 in Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome
Conditions: Acute Myeloid Leukemia; High-Risk and Very High-Risk Myelodysplastic Syndromes Intervention: Drug: SGR-2921 Sponsor: Schrödinger, Inc. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - July 27, 2023 Category: Research Source Type: clinical trials

Gilead To Discontinue Phase 3 ENHANCE Study of Magrolimab Plus Azacitidine in Higher-Risk MDS
FOSTER CITY, Calif.--(BUSINESS WIRE) July 21, 2023 -- Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the Phase 3 ENHANCE study in higher-risk myelodysplastic syndromes (MDS) has been discontinued due to futility based on a planned... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - July 21, 2023 Category: Pharmaceuticals Source Type: clinical trials

A Study to Compare the Efficacy and Safety of Luspatercept in Participants With Myelodysplastic Syndrome (MDS) and Anemia Not Receiving Blood Transfusions
Condition: Myelodysplastic Syndromes Interventions: Biological: Luspatercept; Biological: Epoetin Alfa Sponsor: Bristol-Myers Squibb Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - July 18, 2023 Category: Research Source Type: clinical trials